Med9 Activators
Forskolin directly stimulates adenylyl cyclase, thereby enhancing the production of cyclic AMP (cAMP) within cells. This increase in cAMP levels leads to the activation of protein kinase A (PKA), an enzyme that can phosphorylate various proteins, potentially influencing Med9's activity by modulating the phosphorylation state of proteins within its signaling network. Ionomycin, a calcium ionophore, facilitates the influx of calcium ions into the cytoplasm, which can trigger the activation of a host of calcium-dependent kinases. These kinases, by phosphorylation of target proteins, have the capacity to alter signaling pathways that may converge on Med9, ultimately affecting its function. Phorbol 12-myristate 13-acetate (PMA), a known activator of protein kinase C (PKC), mimics diacylglycerol (DAG), a physiological activator of PKC. The activation of PKC leads to the phosphorylation of a wide range of substrates, which can indirectly influence Med9 by altering the network of protein-protein interactions and signaling cascades that Med9 is part of.
Trichostatin A, a compound that inhibits histone deacetylases (HDACs), can alter chromatin structure and gene expression patterns. By preventing deacetylation, Trichostatin A may lead to an upregulation of proteins that either interact with or regulate the function of Med9. 5-Azacytidine acts as a nucleoside analog, which incorporates into RNA and DNA, and is particularly recognized for its ability to inhibit DNA methyltransferases. This action results in DNA hypomethylation and potentially alters gene expression, possibly affecting proteins that control the activity of Med9. Lithium chloride, a simple inorganic salt, has been found to inhibit glycogen synthase kinase-3 (GSK-3). By disrupting the activity of GSK-3, Lithium chloride can influence the Wnt signaling pathway and thus may result in changes to the protein landscape that affects Med9 activity. MG132, a peptide aldehyde, inhibits the ubiquitin-proteasome pathway, preventing the degradation of proteins. This inhibition can lead to increased levels of regulatory proteins that may enhance Med9 activity by either stabilizing Med9 or affecting its regulatory interactions.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylyl cyclase, increasing levels of cAMP, which in turn activates PKA. PKA phosphorylates target proteins involved in various signaling pathways, thereby it can modulate the activity of Med9 by phosphorylation or inducing changes in cellular signaling that affect Med9. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin increases intracellular calcium levels, leading to the activation of calcium-dependent kinases. These kinases can phosphorylate a wide array of proteins, including those associated with the signaling pathways Med9 is involved in, thus altering Med9's activity within the cell. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which can phosphorylate a broad range of substrates, potentially including those within Med9's regulatory scope, thereby influencing Med9's activity through downstream signaling effects. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is an inhibitor of histone deacetylases (HDACs). By preventing deacetylation, it can lead to a more open chromatin structure and affect gene expression patterns, possibly upregulating proteins that interact with or modify Med9's function. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine incorporates into RNA and DNA and inhibits DNA methyltransferase, leading to hypomethylation of DNA. This alteration in DNA methylation status can result in changes in gene expression, potentially affecting genes encoding proteins that regulate Med9. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride inhibits GSK-3, leading to changes in the Wnt signaling pathway. These changes can affect various proteins' stability and interactions within the cell, potentially including those associated with Med9's regulation. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor that prevents the degradation of proteins, potentially leading to an accumulation of regulatory proteins that can enhance Med9 activity by stabilizing its structure or modulating its interaction with other proteins. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $30.00 $46.00 $82.00 $218.00 | 19 | |
Sodium butyrate is an HDAC inhibitor that can lead to hyperacetylation of histones, affecting gene expression. The resultant changes in protein expression can influence Med9's activity by modifying the cellular environment and the availability of its regulatory factors. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which can affect the MAPK signaling pathway. By inhibiting this pathway, there can be alterations in the signaling cascade that could upregulate proteins which interact or regulate Med9, thus influencing its activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MAPK/ERK kinase, affecting the ERK pathway. This inhibition can lead to changes in the protein expression profile of the cell, potentially enhancing the expression of proteins that can upregulate Med9 activity. | ||||||